1. Home
  2. CNXC vs SRPT Comparison

CNXC vs SRPT Comparison

Compare CNXC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$26.46

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$20.13

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXC
SRPT
Founded
1991
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
CNXC
SRPT
Price
$26.46
$20.13
Analyst Decision
Strong Buy
Hold
Analyst Count
5
28
Target Price
$54.80
$25.40
AVG Volume (30 Days)
1.6M
3.2M
Earning Date
03-24-2026
05-05-2026
Dividend Yield
5.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,825,771,000.00
$2,198,237,000.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.15
15.58
52 Week Low
$24.27
$10.42
52 Week High
$62.14
$67.47

Technical Indicators

Market Signals
Indicator
CNXC
SRPT
Relative Strength Index (RSI) 38.32 56.41
Support Level N/A $16.38
Resistance Level $34.64 $23.01
Average True Range (ATR) 2.15 1.20
MACD -0.47 0.62
Stochastic Oscillator 23.56 49.54

Price Performance

Historical Comparison
CNXC
SRPT

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: